The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene

Toxicologic Pathology

Volumn 26, Issue 6, 1998, Pages 759-768

  Karlsson, Stefan ^a   Iatropoulos, Michael J ^b   Williams, Gary M ^b   Kangas, Lauri ^a,c   Nieminen, L ^a  

^a ORION CORPORATION   (Finland)

^b AMERICAN HEALTH FOUNDATION   (United States)

^c Hormos Medical Ltd   (Finland)

Author keywords

Antiestrogens; Breast cancer; Bromodeoxyuridine; Diethylstilbestrol; Endometrium; Proliferating cell nuclear antigen; Tripheuylethylenes

Indexed keywords

TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS CANCER;

ANIMALIA;

EID: 0031744687     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339802600608     Document Type: Article

References (25)

1. Abdo KM and Kari FW (1996). The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. Exp. Toxicol. Pathol. 48: 129-137.
2. Ashby J, Odum J, and Foster JR (1997). Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul. Toxicol. Pharmacol. 25: 226-231.
3. Astrahantseff KN and Morris JE (1994). Estradiol-17b stimulates proliferation of uterine epithelial cells cultured with stromal cells but not cultured separately. In Vitro Cell. Dev. Biol. 30(suppl. A): 769-776.
4. Carmichael PL, Ugwumadu ANH, Neven P, Hewer AJ, Poon GK, and Phillips DH (1996). Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56: 1475-1479.
5. Carthew P, Edwards RE, Nolan BN, Martin EA, and Smith LL (1996). Tamoxifen associated uterine pathology in rodents: Relevance to women. Carcinogenesis 17: 1577-1582.
6. Chapin RE, Gulati DK, Barnes LH, and Teague JT (1993). The effects of feed restriction on reproductive function in Sprague-Dawley rats. Fundam. Appl. Toxicol. 20: 23-29.
7. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, and Beyth Y (1993). Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br. J. Obstet. Gynaecol. 100: 567-570.
8. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, and Costa A (1996). Effects of tamoxifen on endometrial proliferation. J. Clin. Oncol. 14: 434-440.
9. Dietrich RD (1993). Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit. Rev. toxicol. 23: 77-109.
10. Dragan YP, Vaughan J, Jordan VC, and Pilot HC (1995). Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16: 2733-2741.
11. Friedl A and Jordan VC (1994). What do we know and what don't we know about tamoxifen in the human uterus. Br. Cancer Res. Treat. 31: 27-39.
12. Gratzner HG (1982). Monoclonal antibody to 5-bromo- and 5-io-dodeoxyuridine: a new reagent for detection of DNA replication. Science 218: 474-475.
13. Greaves P, Goonetilleke R, Nunn G, Topham J, and Orton T (1993). Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53: 3919-3924.
14. Grunert G, Neumann G, Porcia M, and Tchernitchin AN (1987). The estrogenic responses to clomiphene in the different cell types of the rat uterus: Morphometrical evaluation. Biol. Reprod. 37: 527-538.
15. Han Y and Liehr JE (1992). Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52: 1360-1363.
16. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, and Williams GM (1993). Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53: 4534-4541.
17. Hayes DF, Vanzyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, and Schoenfelder J (1995). Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13: 2556-2566.
18. Hemminki K, Rajaniemi H, Lindahl B, and Moberger B (1996). Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56: 4374-4377.
19. Hirsimäki P, Hirsimäki Y, Nieminen L, and Payne BJ (1993). Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch. Toxicol. 67: 49-54.
20. Iatropoulos MJ (1993/94). Endocrine considerations in toxicologic pathology. Exp. Toxicol. Pathol. 45: 391-410.
21. International Agency for Research on Cancer (1996). Tamoxifen. In: IARC Monogr. Eval. Carcinog. Risks Humans: Some Pharm. Drugs. IARC, Lyon, France, 66: 253-387.
22. Jordan VC, Allen KE, and Dix CJ (1980). Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 64: 745-759.
23. Karlsson S, Hirsimäki Y, Mäntylä E, Nieminen L, Kangas L, Hirsimäki P, Perry CJ, Mulhern M, Millar P, Handa J, and Williams GM (1996). A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem. Toxicol. 19: 245-266.
24. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey Frink KL, Ma YF, Jee WSS, and Thompson DD (1997). Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20: 31-39.
25. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, and Campbell S (1994). Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321.